Pharmacokinetics
Conditions
Keywords
Sugammadex, Laparoscopic Surgery
Brief summary
The purpose of this study is to illustrate pharmacokinetics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in patients during laparoscopic surgery
Detailed description
48 patients undergoing laparoscopic surgery were divided into 3 groups according to body mass index (BMI), including normal weight group(A group,n=16,18.5kg/m² ≤ BMI ≤ 24.9kg/m²),obese group (B group, n=16, 25≤BMI≤39.9kg/m²) and morbidly obese group (C group, n=16, BMI≥40kg/m²). Vecuronium was continuous infusing to maintain moderate neuromuscular blockade during the laparoscopic surgery and stopped infusing after the laparoscopic procedure. A single dose administration of sugammadex (Sug) 2.0mg/kg according to ideal body weight (IBW) was given at the reappearance of the second twitch of the train-of-four (TOF) response. On one hand, venous blood samples were obtained before administration of Sug and at 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours after administration of Sug to determine plasma concentration of Sug using HPLC-MS. On the other hand, time from start of administration of Sug to recovery of TOF ratio to 0.9 and other clinical indicators were also recorded.
Interventions
DRUGSugammadex
Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
Sponsors
Guangzhou General Hospital of Guangzhou Military Command
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. ASA: Ⅰ\~Ⅲ 2. BMI≥25kg/m² 3. Patients receiving bariatric surgery.
Exclusion criteria
1. Pregnant or lactating women 2. Neuromuscular diseases 3. Malignant hyperthermia or allergic history during general anesthesia 4. Drugs that react with rocuronium and vecuronium were taken
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentration of Sugammadex | 0, 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours | venous blood samples were obtained |
| TOF ratio of Recovery Time | TOF ratio at 30, 60, 90, 120, 150 seconds after administration | time from start of administration of Sug to recovery of TOF ratio to 0.9 and other indicators |
Countries
China
Outcome results
None listed